Tick-Borne Encephalitis Virus IgM Control Serum BC112M

$94.00

Summary

Virion/Serion Diagnostic Kit Control for research use (RUO)
Tick-Borne Encephalitis Virus (TBEV) IgM Control Serum
Applications: ELISA
IgM control serum
Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
3 mL

SKU: BC112M Categories: control serum, Virion/Serion kits Tags: ELISA control serum, IgM, Tick-Borne Encephalitis Virus

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Tick-Borne Encephalitis Virus reactive IgM
species reactivity	Tick-Borne Encephalitis Virus
applications	ELISA
assay type	Indirect & quantitative
available size	3 mL

Tick-Borne Encephalitis Virus IgM Control Serum BC112M

kit
Research area Infectious Disease
Storage Store at 2-8°C.
Associated products FSME/TBE (Tick-Borne Encephalitis) Virus (Premium) Antigen (BA112VS) FSME/TBE (Tick-Borne Encephalitis) Virus Antigen (BA112VSL) Tick-Borne Encephalitis Virus IgG Control Serum (BC112G) Tick-Borne Encephalitis Virus IgM Control Serum (BC112M) Tick-Borne Encephalitis Virus IgG ELISA Kit (ESR112G) Tick-Borne Encephalitis Virus IgM ELISA Kit (ESR112M)

target relevance

human antibody anti-Tick-Borne Encephalitis Virus (TBE/FSME)

Tick-Borne Encephalitis Virus (TBE/FSME)

Description
Virus that causes tick-borne encephalitis (TBE/FSME)

Structure
Tick-borne encephalitis virus (TBEV), also known as FSME virus (Frühsommer-Meningoenzephalitis virus), is an enveloped, positive-sense, single-stranded RNA virus belonging to the genus Flavivirus within the family Flaviviridae. The virus is closely related to other medically important flaviviruses, including West Nile virus, Yellow fever virus, Dengue virus, and Zika virus. TBEV is maintained in nature through transmission cycles involving ixodid ticks, primarily Ixodes ricinus and Ixodes persulcatus, and a variety of wild mammalian hosts. Three major subtypes are recognized: European, Siberian, and Far Eastern. Human infection typically occurs through the bite of an infected tick, although transmission may also occur through the consumption of unpasteurized milk or dairy products from infected animals. The virus is neurotropic and can invade the central nervous system, resulting in severe neurological disease.

Diagnosis
The diagnosis of tick-borne encephalitis virus infection is performed through serological and molecular methods. Detection of TBEV-specific IgM and IgG antibodies using ELISA is the primary laboratory approach and is considered highly sensitive and specific during the neurological phase of disease. Confirmation may be obtained using virus neutralization assays. Molecular detection by reverse transcription polymerase chain reaction (RT-PCR) may identify viral RNA during the early viremic phase but is often less useful after neurological symptoms develop because viremia is typically transient. Cerebrospinal fluid analysis frequently demonstrates pleocytosis and elevated protein concentrations in patients with central nervous system involvement. Accurate laboratory diagnosis is essential because clinical symptoms overlap with those of other viral and bacterial neurological infections.

Symptoms
Tick-borne encephalitis virus infection frequently follows a biphasic course. After an incubation period of approximately seven to fourteen days, the initial phase is characterized by nonspecific flu-like symptoms including fever, fatigue, headache, muscle aches, malaise, and nausea. Following a symptom-free interval, a second phase may occur in which the virus affects the central nervous system, resulting in meningitis, encephalitis, meningoencephalitis, or myelitis. Neurological manifestations may include severe headache, neck stiffness, confusion, impaired consciousness, tremors, paralysis, seizures, and cognitive dysfunction. While many infections remain asymptomatic or mild, severe disease can result in long-term neurological sequelae or death, particularly among older adults and patients infected with more virulent viral subtypes.

Data

FAQ & Publications

Frequently Asked Questions

What applications is the Tick-Borne Encephalitis Virus IgM Control Serum BC112M suitable for?

The Tick-Borne Encephalitis Virus IgM Control Serum BC112M is designed for use as a control in ELISA assays, specifically for indirect and quantitative detection of IgM antibodies against Tick-Borne Encephalitis Virus.

How should the Tick-Borne Encephalitis Virus IgM Control Serum BC112M be stored to maintain stability?

This IgM control serum should be stored at a temperature between 2°C and 8°C to preserve its integrity and ensure reliable assay performance.

Is the Tick-Borne Encephalitis Virus IgM Control Serum BC112M pre-diluted for use with specific ELISA kits?

Yes, the serum is ready-to-use and pre-diluted for compatibility with SERION ELISA classic and SERION ELISA antigen assays, facilitating direct application in these diagnostic kits.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.

Protocols

relevant to this product
BC112M protocol

Documents

#
Please enter your product and batch number here.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Tick-Borne Encephalitis Virus IgM Control Serum BC112M

Data

FAQ & Publications

Protocols

Documents

Related Technical Resources & Posts

Reviews

Related Products

Enterovirus IgM Control Serum BC133M

Candida albicans IgM Control Serum BC117M

Influenza B Virus IgM Control Serum BC1232M

Campylobacter jejuni IgM Control Serum BC139M

Influenza A Virus IgM Control Serum BC1231M

Brucella IgM Control Serum BC116M

Helicobacter pylori IgM Control Serum BC118M

Borrelia burgdorferi IgM Control Serum BC121M

Aspergillus fumigatus IgM Control Serum BC132M

Echovirus IgM Control Serum BC135M

Cytomegalovirus IgM Control Serum BC109M

Coxsackie IgM Virus Control Serum BC134M

Coxiella burnetii Phase 2 IgM Control Serum BC1312M

Chlamydia trachomatis IgM Control Serum BC1372M

Chlamydia pneumoniae IgM Control Serum BC1371M